Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice.

Bermudez LE, Inderlied CB, Kolonoski P, Chee CB, Aralar P, Petrofsky M, Parman T, Green CE, Lewin AH, Ellis WY, Young LS.

Antimicrob Agents Chemother. 2012 Aug;56(8):4202-6. doi: 10.1128/AAC.00320-12. Epub 2012 May 21.

2.

Bacterial identification by 16S rRNA gene PCR-hybridization as a supplement to negative culture results.

Matsuda K, Iwaki KK, Garcia-Gomez J, Hoffman J, Inderlied CB, Mason WH, Iwaki Y.

J Clin Microbiol. 2011 May;49(5):2031-4. doi: 10.1128/JCM.00615-10. Epub 2011 Mar 23.

3.

Down-regulation of atopic dermatitis-associated serum chemokines by wet-wrap treatment: a pilot study.

Ong PY, Ferdman RM, Dunaway T, Church JA, Inderlied CB.

Ann Allergy Asthma Immunol. 2008 Mar;100(3):286-7. doi: 10.1016/S1081-1206(10)60458-9. No abstract available.

PMID:
18426151
4.

EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.

Bermudez LE, Motamedi N, Chee C, Baimukanova G, Kolonoski P, Inderlied C, Aralar P, Wang G, Phan LT, Young LS.

Antimicrob Agents Chemother. 2007 May;51(5):1666-70. Epub 2007 Feb 12.

5.

Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study.

MacGregor RR, Hafner R, Wu JW, Murphy RL, Perlman DC, Bermudez LE, Inderlied CB, Picker LJ, Wallis RS, Andersen JW, Mahon LF, Koletar SL, Peterson DM; ACTG Protocol 341 Team.

AIDS Res Hum Retroviruses. 2005 Aug;21(8):689-95.

PMID:
16131307
7.

Differential virulence of Mycobacterium avium strains isolated from HIV-infected patients with disseminated M. avium complex disease.

Ohkusu K, Bermudez LE, Nash KA, MacGregor RR, Inderlied CB.

J Infect Dis. 2004 Oct 1;190(7):1347-54. Epub 2004 Aug 31.

PMID:
15346348
8.

New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.

Rosowsky A, Forsch RA, Sibley CH, Inderlied CB, Queener SF.

J Med Chem. 2004 Mar 11;47(6):1475-86. Erratum in: J Med Chem. 2004 Jul 1;47(14):3705.

PMID:
14998335
9.

A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome.

Benson CA, Williams PL, Currier JS, Holland F, Mahon LF, MacGregor RR, Inderlied CB, Flexner C, Neidig J, Chaisson R, Notario GF, Hafner R; AIDS Clinical Trials Group 223 Protocol Team.

Clin Infect Dis. 2003 Nov 1;37(9):1234-43. Epub 2003 Oct 3.

PMID:
14557969
10.

Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice.

Bermudez LE, Reynolds R, Kolonoski P, Aralar P, Inderlied CB, Young LS.

Antimicrob Agents Chemother. 2003 Aug;47(8):2685-7.

11.

Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.

Bermudez LE, Kolonoski P, Petrofsky M, Wu M, Inderlied CB, Young LS.

J Infect Dis. 2003 Jun 15;187(12):1977-80. Epub 2003 Jun 4.

PMID:
12792877
12.

Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex.

Woods GL, Williams-Bouyer N, Wallace RJ Jr, Brown-Elliott BA, Witebsky FG, Conville PS, Plaunt M, Hall G, Aralar P, Inderlied C.

J Clin Microbiol. 2003 Feb;41(2):627-31.

15.

Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.

Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Aralar P, Wu M, Young LS.

Antimicrob Agents Chemother. 2001 Jan;45(1):217-22.

16.

Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice.

Bermudez LE, Nash K, Petrofsky M, Young LS, Inderlied CB.

Antimicrob Agents Chemother. 2000 Oct;44(10):2619-22.

17.

Isolation of two subpopulations of Mycobacterium avium within human macrophages.

Bermudez LE, Wu M, Miltner E, Inderlied CB.

FEMS Microbiol Lett. 1999 Sep 1;178(1):19-26.

18.

Mefloquine is active in vitro and in vivo against Mycobacterium avium complex.

Bermudez LE, Kolonoski P, Wu M, Aralar PA, Inderlied CB, Young LS.

Antimicrob Agents Chemother. 1999 Aug;43(8):1870-4.

19.

Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection.

Hafner R, Inderlied CB, Peterson DM, Wright DJ, Standiford HC, Drusano G, Muth K.

J Infect Dis. 1999 Aug;180(2):438-47.

PMID:
10395860
20.

Pediatric transplant grand rounds. A case presentation: skin lesions in a post-lung transplant patient.

Woo MS, Downey S, Inderlied CB, Kaminsky C, Ross LA, Rowland J.

Pediatr Transplant. 1997 Nov;1(2):163-70. No abstract available.

PMID:
10084776
21.

The role of copper on ethambutol's antimicrobial action and implications for ethambutol-induced optic neuropathy.

Kozak SF, Inderlied CB, Hsu HY, Heller KB, Sadun AA.

Diagn Microbiol Infect Dis. 1998 Feb;30(2):83-7.

PMID:
9554173
22.
23.
24.

Adenovirus viremia in human immunodeficiency virus-infected children.

Ferdman RM, Ross L, Inderlied C, Church JA.

Pediatr Infect Dis J. 1997 Apr;16(4):413-5. No abstract available.

PMID:
9109147
25.

Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model.

Bermudez LE, Nash KA, Petrofsky M, Young LS, Inderlied CB.

J Infect Dis. 1996 Dec;174(6):1218-22.

PMID:
8940212
26.

Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex.

Nash KA, Inderlied CB.

Antimicrob Agents Chemother. 1996 Jul;40(7):1748-50. Erratum in: Antimicrob Agents Chemother 1996 Oct;40(10):2442.

27.
28.
29.

Efficacy of azithromycin and rifabutin in preventing infection by Mycobacterium avium complex in beige mice.

Bermudez LE, Petrofsky M, Inderlied CB, Young LS.

J Antimicrob Chemother. 1995 Oct;36(4):641-6.

PMID:
8591938
31.
32.

In-vitro activity of oxazolidinones against Mycobacterium avium complex.

Peters J, Kondo KL, Lee RK, Lin CK, Inderlied CB.

J Antimicrob Chemother. 1995 May;35(5):675-9.

PMID:
7592181
33.

Potential role of roxithromycin against the Mycobacterium avium complex.

Young LS, Bermudez LE, Wu M, Inderlied CB.

Infection. 1995;23 Suppl 1:S28-32.

PMID:
7782113
34.

Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice.

Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Young LS.

Antimicrob Agents Chemother. 1994 Dec;38(12):2717-21.

35.

Antimycobacterial susceptibility testing: present practices and future trends.

Inderlied CB.

Eur J Clin Microbiol Infect Dis. 1994 Nov;13(11):980-93. Review.

PMID:
7698124
36.
37.

Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages.

Inderlied CB, Barbara-Burnham L, Wu M, Young LS, Bermudez LE.

Antimicrob Agents Chemother. 1994 Aug;38(8):1838-43.

38.

Orally administered clarithromycin for the treatment of systemic Mycobacterium avium complex infection in children with acquired immunodeficiency syndrome.

Husson RN, Ross LA, Sandelli S, Inderlied CB, Venzon D, Lewis LL, Woods L, Conville PS, Witebsky FG, Pizzo PA.

J Pediatr. 1994 May;124(5 Pt 1):807-14.

PMID:
8176574
39.
40.

Practical issues in the antibiotic and immunotherapy of Mycobacterium avium disease in immunocompromised patients.

Young LS, Bermudez LE, Inderlied CB.

Res Microbiol. 1994 Mar-Apr;145(3):206-9. Review. No abstract available.

PMID:
7809473
41.

The Mycobacterium avium complex.

Inderlied CB, Kemper CA, Bermudez LE.

Clin Microbiol Rev. 1993 Jul;6(3):266-310. Review.

42.

Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex.

Bermudez LE, Wu M, Young LS, Inderlied CB.

J Infect Dis. 1992 Oct;166(4):923-6.

PMID:
1445599
43.

Mycobacteria and AIDS: treatment, prevention and future prospects.

Young LS, Bermudez LE, Inderlied CB.

Res Microbiol. 1992 May;143(4):420-2. Review. No abstract available.

PMID:
1455070
44.

Mycobacterium avium complex in AIDS.

Bermudez LE, Inderlied CB, Young LS.

Curr Clin Top Infect Dis. 1992;12:257-81. Review. No abstract available.

PMID:
1642801
45.

Disseminated Mycobacterium avium complex infection.

Inderlied CB, Kemper CA.

AIDS Clin Rev. 1992:131-72. Review. No abstract available.

PMID:
1606056
46.

Stimulation with cytokines enhances penetration of azithromycin into human macrophages.

Bermudez LE, Inderlied C, Young LS.

Antimicrob Agents Chemother. 1991 Dec;35(12):2625-9.

47.

Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS.

Young LS, Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied CB.

Lancet. 1991 Nov 2;338(8775):1107-9.

PMID:
1682544
48.

Detection of rubella virus gene sequences by enzymatic amplification and direct sequencing of amplified DNA.

Eggerding FA, Peters J, Lee RK, Inderlied CB.

J Clin Microbiol. 1991 May;29(5):945-52.

49.

Imipenem/cilastatin treatment of bacterial meningitis in children.

Wong VK, Wright HT Jr, Ross LA, Mason WH, Inderlied CB, Kim KS.

Pediatr Infect Dis J. 1991 Feb;10(2):122-5.

PMID:
2062603
50.

Antimicrobial susceptibility of clinical isolates of Haemophilus influenzae to ampicillin-sulbactam.

Mortensen JE, LaRocco M, Himes SL, Inderlied C, Daly JA, Campos JM, Mendelman PM.

Diagn Microbiol Infect Dis. 1990 Jul-Aug;13(4):341-4.

PMID:
2076596

Supplemental Content

Loading ...
Support Center